Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
Imprimis Pharmaceuticals reports 2020 executive compensation
By ExecPay News
Published: April 23, 2021
Imprimis Pharmaceuticals reported fiscal year 2020 executive compensation information on April 23, 2021.
In 2020, three executives at Imprimis Pharmaceuticals received on average a compensation package of $1.3M, a 19% increase compared to previous year.
Average pay of disclosed executives at Imprimis Pharmaceuticals
Mark L. Baum, Chief Executive Officer, received $2.5M in total, which increased by 80% compared to 2019. 38% of Baum's compensation, or $948K, was in option awards. Baum also received $256K in non-equity incentive plan, $570K in salary, $697K in stock awards, as well as $12K in other compensation.
Andrew R. Boll, Chief Financial Officer, received a compensation package of $1M, which decreased by 3% compared to previous year. 40% of the compensation package, or $410K, was in salary.
John P. Saharek, President, ImprimisRx, earned $534K in 2020, a 45% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 23, 2021.